Loading...
•
Mar 31, 2024
Bicycle Q1 2024 Earnings Report
Reported first quarter financial results and recent business progress.
Key Takeaways
Bicycle Therapeutics reported its first quarter financial results, highlighting the initiation of the Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer and progress across its pipeline.
Multiple preclinical and clinical abstracts accepted for presentation at 2024 ASCO Annual Meeting and AACR Annual Meeting.
Continued progress across research and development (R&D) pipeline, with numerous clinical data readouts and updates expected in 2H 2024.
Mike Hannay, D.Sc., FRPharmS, promoted to Chief Product and Supply Chain Officer
Cash and cash equivalents of $457.0 million as of March 31, 2024, expected to provide financial runway into 2026
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...